hydralazine has been researched along with Left Ventricular Hypertrophy in 26 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to compare the long-term effects on ambulatory blood pressure and left ventricular hypertrophy of hydralazine and lisinopril we studied 30 patients, all males, still hypertensive (diastolic blood pressure > or = 95 mm Hg) despite combined beta-blocker/diuretic therapy and with echocardiographic evidence of left ventricular hypertrophy (left ventricular mass index > or = 1." | 9.08 | Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. ( Corradi, L; Fogari, R; Lusardi, P; Mugellini, A; Tettamanti, F; Zoppi, A, 1995) |
| " Here, we aimed to determine whether lowering blood pressure with hydralazine might prevent inflammation and cardiac fibrosis in response to angiotensin II." | 7.77 | Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. ( Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011) |
| " In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics." | 7.70 | Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. ( El Salibi, E; Nguyen, T; Rouleau, JL, 1998) |
| "In order to compare the long-term effects on ambulatory blood pressure and left ventricular hypertrophy of hydralazine and lisinopril we studied 30 patients, all males, still hypertensive (diastolic blood pressure > or = 95 mm Hg) despite combined beta-blocker/diuretic therapy and with echocardiographic evidence of left ventricular hypertrophy (left ventricular mass index > or = 1." | 5.08 | Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. ( Corradi, L; Fogari, R; Lusardi, P; Mugellini, A; Tettamanti, F; Zoppi, A, 1995) |
| " Here, we aimed to determine whether lowering blood pressure with hydralazine might prevent inflammation and cardiac fibrosis in response to angiotensin II." | 3.77 | Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. ( Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011) |
| " Rats were exposed to mechanical overload (ascending aortic stenosis), increased levels of circulating ANG II (ANG II infusion combined with hydralazine), or adrenergic stimulation (infusion of norepinephrine in a subpressor dose) for 7 days." | 3.71 | Predominant activation of endothelin-dependent cardiac hypertrophy by norepinephrine in rat left ventricle. ( Ehmke, H; Faulhaber, J; Moser, L; Wiesner, RJ, 2002) |
| " In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics." | 3.70 | Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. ( El Salibi, E; Nguyen, T; Rouleau, JL, 1998) |
| "We investigated the pathophysiological significance of adrenomedullin (AM) in the development of left ventricular hypertrophy (LVH)." | 3.70 | Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. ( Dohi, K; Horio, T; Kangawa, K; Matsuo, H; Morimoto, A; Nagaya, N; Nishikimi, T; Yoshihara, F, 1999) |
| "Effects of reduction of blood pressure and regression of left ventricular hypertrophy following hydralazine and captopril therapy on ischemic cardiac function and myocardial metabolism were studied in spontaneously hypertensive rats (SHR)." | 3.68 | Effect of regression of cardiac hypertrophy on ischemic myocardial damage in spontaneously hypertensive rats. ( Abe, M; Haneda, T; Okamoto, K, 1993) |
| "The effects of enalapril and hydralazine upon left ventricular hypertrophy in SHRSP were consistent with their respective effects upon blood pressure." | 3.68 | Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats. ( Cleary, EG; King, RA; Krishnan, R; Smith, RM, 1992) |
| "Untreated essential hypertension is associated with left ventricular hypertrophy (LVH) and structural changes in resistance vessels." | 2.68 | Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. ( Aalkjaer, C; Holm, M; Lederballe, O; Mulvany, M; Mørn, B; Schroeder, AP; Sihm, I; Thygesen, K, 1995) |
| "Echocardiography revealed concentric left ventricular hypertrophy in male WT mice, whereas ERβ(-/-) females developed dilative left ventricular hypertrophy." | 1.37 | Estrogen receptor-beta signals left ventricular hypertrophy sex differences in normotensive deoxycorticosterone acetate-salt mice. ( Catar, R; Chaykovska, L; da Costa Goncalves, AC; Dragun, D; Gross, V; Gürgen, D; Gustafsson, JÅ; Hegner, B; Hoff, U; Kintscher, U; Kusch, A; Luft, FC; Slowinski, T, 2011) |
| "They developed more left ventricular hypertrophy and more renal hypertrophy after 6 weeks of DOCA-salt+hydralazine compared with female mice." | 1.35 | Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism. ( Akashi, YJ; da Costa Goncalves, AC; de Windt, LJ; Dragun, D; Gross, V; Gürgen, D; Hegner, B; Karatas, A; Kintscher, U; Luft, FC; Regitz-Zagrosek, V; Schubert, C, 2008) |
| "Uremia was induced in male Spraugue Dawley rats by 5/6 nephrectomy." | 1.32 | Gene expression in uremic left ventricular hypertrophy: effects of hypertension and anemia. ( Chang, SL; Draksharapu, A; Mak, RH; Pak, YK, 2004) |
| "Treatment with captopril significantly reduced the incidence of VT/Vf although hydralazine failed to reduce the incidence." | 1.29 | [Effect of chronic antihypertensive treatment on ischemia-induced lethal ventricular tachyarrhythmias and electrophysiological property in hypertrophied rat hearts]. ( Yokoshiki, H, 1993) |
| "Hydralazine-treated SHRs had a collagen I:III ratio of 10." | 1.29 | Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure. ( Mukherjee, D; Sen, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (53.85) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zamani, P | 1 |
| Akers, S | 1 |
| Soto-Calderon, H | 1 |
| Beraun, M | 1 |
| Koppula, MR | 1 |
| Varakantam, S | 1 |
| Rawat, D | 1 |
| Shiva-Kumar, P | 1 |
| Haines, PG | 1 |
| Chittams, J | 1 |
| Townsend, RR | 1 |
| Witschey, WR | 1 |
| Segers, P | 1 |
| Chirinos, JA | 1 |
| Gürgen, D | 2 |
| Hegner, B | 2 |
| Kusch, A | 1 |
| Catar, R | 1 |
| Chaykovska, L | 1 |
| Hoff, U | 1 |
| Gross, V | 2 |
| Slowinski, T | 1 |
| da Costa Goncalves, AC | 2 |
| Kintscher, U | 2 |
| Gustafsson, JÅ | 1 |
| Luft, FC | 2 |
| Dragun, D | 2 |
| Qi, G | 1 |
| Jia, L | 1 |
| Li, Y | 1 |
| Bian, Y | 1 |
| Cheng, J | 1 |
| Li, H | 1 |
| Xiao, C | 1 |
| Du, J | 1 |
| Nako, H | 1 |
| Kataoka, K | 1 |
| Koibuchi, N | 1 |
| Dong, YF | 1 |
| Toyama, K | 1 |
| Yamamoto, E | 1 |
| Yasuda, O | 1 |
| Ichijo, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Mak, RH | 1 |
| Chang, SL | 1 |
| Draksharapu, A | 1 |
| Pak, YK | 1 |
| Lee, TM | 1 |
| Lin, MS | 1 |
| Tsai, CH | 1 |
| Chang, NC | 1 |
| Karatas, A | 1 |
| de Windt, LJ | 1 |
| Schubert, C | 1 |
| Akashi, YJ | 1 |
| Regitz-Zagrosek, V | 1 |
| Sihm, I | 1 |
| Schroeder, AP | 1 |
| Aalkjaer, C | 1 |
| Holm, M | 1 |
| Mørn, B | 1 |
| Mulvany, M | 1 |
| Thygesen, K | 1 |
| Lederballe, O | 1 |
| Yokoshiki, H | 1 |
| Kojima, M | 1 |
| Shiojima, I | 1 |
| Yamazaki, T | 1 |
| Komuro, I | 1 |
| Zou, Z | 1 |
| Wang, Y | 1 |
| Mizuno, T | 1 |
| Ueki, K | 1 |
| Tobe, K | 1 |
| Kadowaki, T | 1 |
| Lee, TH | 1 |
| Hamilton, MA | 1 |
| Stevenson, LW | 1 |
| Moriguchi, JD | 1 |
| Fonarow, GC | 1 |
| Child, JS | 1 |
| Laks, H | 1 |
| Walden, JA | 1 |
| Okamoto, K | 1 |
| Abe, M | 1 |
| Haneda, T | 1 |
| Mukherjee, D | 1 |
| Sen, S | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Mugellini, A | 1 |
| Tettamanti, F | 1 |
| Lusardi, P | 1 |
| Corradi, L | 1 |
| Susic, D | 1 |
| Nuñez, E | 1 |
| Frohlich, ED | 1 |
| Prakash, O | 1 |
| Reddy, DS | 1 |
| Singh, M | 1 |
| Ghosh, S | 1 |
| Ganguly, NK | 1 |
| Donohue, TJ | 1 |
| Dworkin, LD | 1 |
| Ma, J | 1 |
| Lango, MN | 1 |
| Catanese, VM | 1 |
| Grimm, D | 1 |
| Kromer, EP | 1 |
| Böcker, W | 1 |
| Bruckschlegel, G | 1 |
| Holmer, SR | 1 |
| Riegger, GA | 1 |
| Schunkert, H | 1 |
| Nguyen, T | 1 |
| El Salibi, E | 1 |
| Rouleau, JL | 1 |
| Morimoto, A | 1 |
| Nishikimi, T | 1 |
| Yoshihara, F | 1 |
| Horio, T | 1 |
| Nagaya, N | 1 |
| Matsuo, H | 1 |
| Dohi, K | 1 |
| Kangawa, K | 1 |
| Ikeda, Y | 1 |
| Nakamura, T | 1 |
| Takano, H | 1 |
| Kimura, H | 1 |
| Obata, JE | 1 |
| Takeda, S | 1 |
| Hata, A | 1 |
| Shido, K | 1 |
| Mochizuki, S | 1 |
| Yoshida, Y | 1 |
| Kai, T | 1 |
| Ishikawa, K | 1 |
| Tsotetsi, OJ | 1 |
| Woodiwiss, AJ | 1 |
| Netjhardt, M | 1 |
| Qubu, D | 1 |
| Brooksbank, R | 1 |
| Norton, GR | 1 |
| Kamide, K | 1 |
| Rakugi, H | 1 |
| Higaki, J | 1 |
| Okamura, A | 1 |
| Nagai, M | 1 |
| Moriguchi, K | 1 |
| Ohishi, M | 1 |
| Satoh, N | 1 |
| Tuck, ML | 1 |
| Ogihara, T | 1 |
| Moser, L | 1 |
| Faulhaber, J | 1 |
| Wiesner, RJ | 1 |
| Ehmke, H | 1 |
| King, RA | 1 |
| Smith, RM | 1 |
| Krishnan, R | 1 |
| Cleary, EG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction[NCT01516346] | Phase 2 | 44 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Diastolic mitral annular velocity measured at the basal septal mitral annulus (NCT01516346)
Timeframe: 24 weeks
| Intervention | cm/s (Mean) |
|---|---|
| Isosorbide Dinitrate | 6.8 |
| Isosorbide Dinitrate + Hydralazine | 7.3 |
| Placebo | 6.5 |
LV mass measured by MRI, in grams normalized to height in meters raised to the 1.7 power (m^1.7) (NCT01516346)
Timeframe: 24 weeks
| Intervention | grams / meters ^1.7 (Mean) |
|---|---|
| Isosorbide Dinitrate | 68.2 |
| Isosorbide Dinitrate + Hydralazine | 66.2 |
| Placebo | 67.2 |
Myocardial extracellular volume, expressed as percent of total tissue volume, measured by MRI (T1 mapping pre and post-gadolinium administration) (NCT01516346)
Timeframe: 24 weeks
| Intervention | Percentage (Mean) |
|---|---|
| Isosorbide Dinitrate | 29.0 |
| Isosorbide Dinitrate + Hydralazine | 31.3 |
| Placebo | 29.5 |
Quality of life, assessed with the Kansas City cardiomyopathy questionnaire (overall summary score, which ranges from 0 to 100). Higher values imply better quality of life. (NCT01516346)
Timeframe: 24 weeks
| Intervention | Points on a scale (Mean) |
|---|---|
| Isosorbide Dinitrate | 62.1 |
| Isosorbide Dinitrate + Hydralazine | 44.9 |
| Placebo | 62.1 |
The dimensionless ratio of backward (reflected) to forward wave amplitude. Higher values imply more wave reflection. (NCT01516346)
Timeframe: 24 weeks
| Intervention | dimensionless ratio (Mean) |
|---|---|
| Isosorbide Dinitrate | 0.38 |
| Isosorbide Dinitrate + Hydralazine | 0.44 |
| Placebo | 0.37 |
3 trials available for hydralazine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Echocardiogr | 2017 |
Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Drug Therapy, Co | 1995 |
Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 1995 |
23 other studies available for hydralazine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Estrogen receptor-beta signals left ventricular hypertrophy sex differences in normotensive deoxycorticosterone acetate-salt mice.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Desoxycor | 2011 |
Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent.
Topics: Angiotensin II; Animals; Blood Pressure; Fibrosis; Hydralazine; Hypertrophy, Left Ventricular; Infla | 2011 |
Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Biphenyl Compounds; Blood Pressure; Blo | 2012 |
Gene expression in uremic left ventricular hypertrophy: effects of hypertension and anemia.
Topics: Actins; Anemia; Animals; Atrial Natriuretic Factor; Erythropoietin; Gene Expression; Heart Ventricle | 2004 |
Effect of pravastatin on left ventricular mass in the two-kidney, one-clip hypertensive rats.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Natriuretic Factor; Echocardiography; Gene Expression Regula | 2006 |
Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcineurin; Desoxycorticosterone; Echocardiograph | 2008 |
[Effect of chronic antihypertensive treatment on ischemia-induced lethal ventricular tachyarrhythmias and electrophysiological property in hypertrophied rat hearts].
Topics: Action Potentials; Animals; Captopril; Drug Administration Schedule; Electrophysiology; Hemodynamics | 1993 |
Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Hydra | 1994 |
Impact of left ventricular cavity size on survival in advanced heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Body Constitution; Cause of Death; Cohort Studies; Death, | 1993 |
Effect of regression of cardiac hypertrophy on ischemic myocardial damage in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Captopril; Hydralazine; Hypertrophy, Left Ventricular; In Vitro Techniques; | 1993 |
Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure.
Topics: Animals; Blood Pressure; Captopril; Collagen; Hydralazine; Hypertension; Hypertrophy, Left Ventricul | 1993 |
Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Heart Ventricles; Hemodynamics | 1996 |
Role of cardiac renin-angiotensin system in the development of pressure-overload left ventricular hypertrophy in rats with abdominal aortic constriction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Abdominal; Blood Pressure; Body Weight; Ca | 1996 |
Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Enalapril; Heart; Hydralazine; Hypertension; Hyper | 1997 |
Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Extracellular Matrix Pro | 1998 |
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pac | 1998 |
Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats.
Topics: Adrenomedullin; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 1999 |
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Lisinopril reduces left ventricular hypertrophy and cardiac polyamine concentrations without a reduction in left ventricular wall stress in transgenic Tsukuba hypertensive mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Hydralazine; Hypertension; Hypertrophy, Left Ventr | 2000 |
Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Collagen; Heart Failure; Heart Ventri | 2001 |
The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Blood Glucose; Blood | 2002 |
Predominant activation of endothelin-dependent cardiac hypertrophy by norepinephrine in rat left ventricle.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Aortic Valve Stenosis; Atrial Natriuretic F | 2002 |
Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; DNA; Elastin; Enalapril; Heart Ventricles; Hydralazine; Hypert | 1992 |